Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - LU
$ 0.69
-11.5 %
$ 77.8 M
Market Cap
1.35
P/E
CASH FLOW STATEMENT
14.1 M
OPERATING CASH FLOW
-28.8 M
INVESTING CASH FLOW
-13.6 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Procaps Group S.A.
| Net Income | 42.5 M |
| Depreciation & Amortization | 16.8 M |
| Capital Expenditures | -31.6 M |
| Stock-Based Compensation | 0 |
| Change in Working Capital | -25.6 M |
| Others | -20.4 M |
| Free Cash Flow | -17.5 M |
Cash Flow
Millions
| Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|
| OPERATING CASH FLOW | ||||
| Net Income | 42.5 | (100.9) | (10.4) | (17.0) |
| Depreciation & Amortization | 16.8 | 15.1 | 16.5 | 16.5 |
| Deferred Income Tax | 10.2 | 13.7 | 11.3 | 7.0 |
| Stock Based Compensation | 0 | (8.4) | (15.0) | (15.5) |
| Other Operating Activities | (29.8) | 152.6 | 54.5 | 43.0 |
| Change in Working Capital | (25.6) | (34.8) | 14.1 | 34.3 |
| Cash From Operations | 14.1 | 37.3 | 70.9 | 68.3 |
| INVESTING CASH FLOW | ||||
| Capital Expenditures | (31.6) | (24.5) | (17.9) | (19.7) |
| Other Items | 2.7 | 0.8 | 0.8 | 7.6 |
| Cash From Investing Activities | (28.8) | (23.7) | (17.1) | (12.1) |
| FINANCING CASH FLOW | ||||
| Common Stock Repurchased | 0 | (45.0) | 0 | 0 |
| Total Debt Repaid | 3.5 | (0.4) | (19.6) | (30.7) |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | (17.2) | 103.4 | (20.9) | (16.3) |
| Cash From Financing Activities | (13.6) | 58.0 | (40.5) | (46.9) |
| CHANGE IN CASH | ||||
| Net Change In Cash | (29.1) | 67.9 | 2.2 | (0.8) |
| FREE CASH FLOW | ||||
| Free Cash Flow | (17.5) | 12.8 | 53.0 | 48.6 |